Also listed on SenoRx, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Term ended no later than Nov 6, 2026 · Medium confidence
20-year base term ended Nov 6, 2026
Held by Hologic, Inc.
Filed Nov 6, 2006 as application 11/593,952 · Granted Aug 5, 2008
Base term, 20 years from filing
Today
Ended no later than Nov 6, 2026
2006
2026
Clock starts
Nov 6, 2006
Nov 6, 2006
Ended no later than
Nov 6, 2026
Nov 6, 2026
Granted
Aug 5, 2008
Aug 5, 2008
base term
after the term ends
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
20
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. All three maintenance fees were paid, so no fee lapse ended it. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 6, 2006, when this application, 11/593,952, was filed | Nov 6, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | no later than Nov 6, 2026 | Medium confidence |
This family
| US 7,413,539 | Term ended Nov 2025 | Nov 2025 |
| US 8,079,946 | In force Apr 2029 | Apr 2029 |
| US 7,465,268 | Lapsed on the fee record Dec 2020 | Dec 2020 |
| US 7,517,310 | Lapsed on the fee record Apr 2017 | Apr 2017 |
| US 7,407,476 | this patent no later than Nov 2026 | no later than Nov 2026 |
| Application PCT/US2006/043891 | PCT application no patent term | no patent term |
| Application PCT/US2006/044067 | PCT application no patent term | no patent term |
| US 8,057,379 | Term ended Nov 2025 | Nov 2025 |
8 of 20 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jan 22, 2007 Reel 18794, frame 585 | Lubock, Paul; Jones, Michael L. | Senorx, Inc. | Assignment of Assignor's Interest |
| Jun 3, 2013 Reel 30530, frame 229 | Senorx, Inc. | Hologic, Inc. | Assignment of Assignor's Interest |
| Jul 9, 2013 Reel 30755, frame 31 | Hologic, Inc.; Biolucent, LLC; Cytyc Corporation; Cytyc Surgical Products, Limited Partnership; Direct Radiogrphy Corp.; Suros Surgical Systems, Inc.; Third Wave Technologies, Inc.; Gen-probe, Incorporated | Goldman Sachs Bank USA | Security Agreement |
| Jul 17, 2015 Reel 36127, frame 538 | Goldman Sachs Bank USA, as Collateral Agent | Hologic, Inc.; Biolucent, LLC; Cytyc Corporation; Cytyc Surgical Products, Limited Partnership; Direct Radiography Corp.; Suros Surgical Systems, Inc.; Third Wave Technologies, Inc.; Gen-Probe Incorporated | Security Interest Release R/F 030755 0031 |
| Jul 17, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Hologic, Inc. | Security Interest Release R/F 030755 0031 |
| Jul 17, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Biolucent, LLC | Security Interest Release R/F 030755 0031 |
| Jul 17, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Cytyc Corporation | Security Interest Release R/F 030755 0031 |
| Jul 17, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Cytyc Surgical Products, Limited Partnership | Security Interest Release R/F 030755 0031 |
| Jul 17, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Direct Radiography Corp. | Security Interest Release R/F 030755 0031 |
| Jul 17, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Suros Surgical Systems, Inc. | Security Interest Release R/F 030755 0031 |
| Jul 17, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Third Wave Technologies, Inc. | Security Interest Release R/F 030755 0031 |
| Jul 17, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Gen-Probe Incorporated | Security Interest Release R/F 030755 0031 |
| Aug 7, 2015 Reel 36307, frame 199 | Hologic, Inc.; Biolucent, LLC; Cytyc Corporation; Cytyc Surgical Products, Limited Partnership; Direct Radiography Corp.; Gen-Probe Incorporated; Gen-Probe Prodesse, Inc.; Suros Surgical Systems, Inc.; Third Wave Technologies, Inc. | Bank of America, N.A., as Collateral Agent | Security Agreement |
| Apr 28, 2026 Reel 75566, frame 39 | Bank of America, N.A., as Collateral Agent | Hologic, Inc., on Its Own Behalf and as Successor-by-Merger to Direct Radiography Corp.; Cytyc Corporation, on Its Own Behalf and as Successor-by-Merger to Biolucent, LLC; Cytyc Surgical Products, LLC, as Successor-by-Conversion to Cytyc Surgical Products, Limited Partnership; Gen-Probe Incorporated, on Its Own Behalf and as Successor-by-Merger to Third Wave Technologies, Inc.; Gen-Probe Prodesse, Inc.; Suros Surgical Systems, Inc. | Release of Security Interest |
| Apr 28, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Hologic, Inc., on Its Own Behalf and as Successor-by-Merger to Direct Radiography Corp. | Release of Security Interest |
| Apr 28, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Cytyc Corporation, on Its Own Behalf and as Successor-by-Merger to Biolucent, LLC | Release of Security Interest |
| Apr 28, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Cytyc Surgical Products, LLC, as Successor-by-Conversion to Cytyc Surgical Products, Limited Partnership | Release of Security Interest |
| Apr 28, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Gen-Probe Incorporated, on Its Own Behalf and as Successor-by-Merger to Third Wave Technologies, Inc. | Release of Security Interest |
| Apr 28, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Gen-Probe Prodesse, Inc. | Release of Security Interest |
| Apr 28, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Suros Surgical Systems, Inc. | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Note
A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed
Open question
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Nov 6, 2026. We will not guess the cap.
Citations
53
later US patents cite this one
That is top 25% of utility patents granted in 2008 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
This computed term ends no later than the date shown; an unresolved terminal disclaimer may end it earlier. Related patents and pending applications may cover overlapping subject matter.